公开(公告)号：US20230278991A1

公开(公告)日：2023-09-07

申请号：US18113859

申请日：2023-02-24

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D405/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula (I)




and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20210179594A1

公开(公告)日：2021-06-17

申请号：US16950393

申请日：2020-11-17

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US10954221B2

公开(公告)日：2021-03-23

申请号：US16902807

申请日：2020-06-16

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20200325121A1

公开(公告)日：2020-10-15

申请号：US16902807

申请日：2020-06-16

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D471/04 ,  C07D417/14

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20230382899A1

公开(公告)日：2023-11-30

申请号：US18031380

申请日：2021-10-13

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo ,  Zheng Jane Li ,  Xiawei Jiang ,  Pengyuan Chen

IPC: C07D405/14

CPC classification number: C07D405/14 ,  C07B2200/13

Abstract: Crystalline forms of Compound (A) represented by the following structural formula, and their corresponding pharmaceutical compositions, are disclosed. The crystalline forms are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating or preventing diseases or conditions such as type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.

公开(公告)号：US11591321B2

公开(公告)日：2023-02-28

申请号：US16950393

申请日：2020-11-17

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula (III) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.